Asthma is one of them Maximum Expensive disease in the United States. Despite the recent measures, until the inlet manufacturer has fallen, there is still a lot to do to make asthma treatment cheaper.
22 or more million Americans have asthma. Half of adults and almost 90%of children, allergies. There is this fee Grew up It seems to be due to climate change since 1996.
There are two major types of inhaler to manage asthma: Daily controller maintain Relief for flare up. Depending on the seriousness of the symptoms, both patients can use both types. The patient can also choose to treat the fundamental allergies. ImmunotherapyTotally by avoiding antihistamines and/or allergic triggers.
But some of these asthma treatments do not reach many patients.
one study Of the 130,000 participants, allergic asthma patients found 39% greater annually. gun Health care costs and 79% larger annual Asthma Medical cost than asthma patients, not allergies. They had a lot more pharmacy claims, outpatient patients and emergency room visits. It was also more likely to have skin and/or blood allergic tests.
All, the author calculated that allergic asthma patients paid more than $ 1100 a year than non -allergic asthma patients. However, this did not include the cost of treatment or costs that can be purchased without prescriptions such as antihistamines and cospray. Immunotherapy ) Their results did not indicate how well the patient’s asthma was controlled, and the cost of health care is usually higher In the case of uncontrolled asthma patients.
Also, inspection According to the US Senate Committee, asthma drugs have found much more expensive in the United States than elsewhere. Astrazeneca, for example, charges $ 645 in the United States for only $ 49 in the United Kingdom. Similarly, Teva Pharmaceuticals charges $ 286 in the United States for $ 9 in inhaler in Germany.
Fairly, some pharmaceutical companies deal with these high prices.
For example, astrazeneca and GSK are followExample of major insulin Price cut with manufacturers. These companies have a price upper limit of $ 35 per month for the inhaler, but they are diverse and patients are still not benefiting.
Some companies approve the general options for brand inhaler. For example, GSK recently stopped Flovent. often Because prescribed maintenance suctions make it cheaper general Instead version. (It is worth noting that this sudden change causes confusion for some patients who need it. scramble To find a similar prescription for the middle.)
Despite these positive changes, the entire system still remains defect. Consider patent protection and monopoly protection of food pharmaceuticals.
The US Patent and Trade Office allows pharmaceutical companies to sell new medicines to compensate for innovation. Set the time Generally 20 years without competition. Food and pharmacies can also provide manufacturers with monopoly on various periods and reasons. However, due to these protection, there were over 50 patents. approval In the case of brand inhaler from 1986 to 2020, there are three general competitions that later faced three general competition. The worse is some pharmaceutical companies. Non -ethical Practices to expand market control longer.
Still, there is a way to solve this. The Senate has recently passed both parties. bill It can be blocked Product hoppingIt is one of the non -ethical practices that the manufacturer stops the production of almost expired products and starts selling new and very similar versions, and effectively restarting patent protection. This was common Albu Terol Structural inhaler, expensive payer and billions of patients. Signing a law can increase the speed of generic launching on the market and ultimately lower the price of patients.
America Value -based priceThe price is based on drug efficiency and the quality of life that patients see. In order to determine the fair price, various cost analysis can be used. Successful In Europe australia With inhaler.
Asthma treatment is expensive and complete. But asthma patients don’t have to worry about how to pay. Although the cost can be minimized, federal policies must balance profitability, economics and innovation.
The study of this work was supported by Arnold Ventures.
